Last year, however, the news broke that Invesco is selling its Intelliflo business to the PE firm Carlyle. In the process, ...
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement ...
Immix Biopharma reported promising Phase 2 clinical trial results for its CAR-T therapy NXC-201, showing a 75% complete response rate in patients with relapsed/refractory AL amyloidosis. The results ...
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the ...
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced ...
Immix Biopharma, Inc. (NASDAQ:IMMX) filed a report with the Securities and Exchange Commission on Wednesday stating that it has submitted newly dated consents from its current and former independent ...
Hosted on MSN
AITX Partners with Immix for Enhanced AI Solutions
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Artificial ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from Immix ...
Immix Biopharma, Inc. (IMMX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback